A new study published by the CGT Catapult & the Office of Health Economics presents a new method of quantifying the economic impact of cell & gene therapies. The research indicates that wider adoption of advanced therapies could unlock billions for the UK economy. Read the study: lnkd.in/eGDdTXwN

A huge thank you to everyone involved for making "AI Applications in Preclinical Assessment of ATMPs" such a success last week. We’ll be sharing a full event write-up from this session, covering: - Key takeaways on AI’s role - Regulatory perspectives - Data sharing opportunities

Autolomous Ltd and the Cell and Gene Therapy Catapult have demonstrated how digital platforms can transform #cell & #gene therapy manufacturing. Read the whitepaper to learn how digital technologies can drive scalability, efficiency & cost-effectiveness in #ATMP manufacturing: ow.ly/KGIt50X6U31

Regulatory update 🔔: FDA proposes guidance on using overall survival endpoints in cancer drug trials. Learn more in the August edition of our Regulatory Round-up: ow.ly/ZaXB50WV8TT #ATMPs #AdvancedTherapies

Regulatory update 🔔: MHRA designated as WHO-Listed Authority - a milestone for UK life sciences and global health. This recognition affirms the MHRA’s commitment to the highest international standards in the regulation of medical products. Learn more: ow.ly/9mCG50WP80o

We're having a great time in Barcelona for Advanced Therapies Europe! This morning Rhys Macown, one of our lead scientists, led a fantastic panel discussion as part of our Manufacturing Transformation Workshop: Automation for Optimum Patient Outcomes. Upcoming events: ct.catapult.org.uk/events

The Innovate UK Biomedical Catalyst Accelerator Future Medicines is now open for applications! We’re proud to be a partner on this national programme supporting UK innovators developing the next generation of medical treatments and technologies. Apply today: lyvalabs.com/future-medic...

Are you following the Centre of Excellence in Regulatory Science and Innovation for Advanced Therapies (CERSI-AT) yet? CERSI-AT drives collaborative activities to ensure the UK has a world-leading regulatory environment that best supports ATMP innovation. Follow: www.linkedin.com/showcase/cen...

In this interview, Mateusz Filipiak, Scientist at CGT Catapult, discusses his involvement in the SMARTER project, involving the development of a smart bioprocessing platform for autologous #CellTherapy. Read the interview: ct.catapult.org.uk/news/r-d-pro...

🔊 Last month, @cgtcatapult.bsky.social, supported by @innovateuk.bsky.social made its first Cross-Catapult Pilot investment in Spliceor, supporting the development of #GeneTherapy for liver cancer 🧬 https://loom.ly/CCBvmg4

Scottish academics – applications close in less than 1 week! 🚨 Apply to our competition to gain expert support in developing a Target Product Profile (TPP) for your #AdvancedTherapy Check out how we supported two academics from the University of Aberdeen below 👇 Apply now: lnkd.in/etGYMQzq

Regulatory update 🔔: MHRA's new modular manufacture and point of care regulations have come into effect. Hospitals in the UK now have a pathway to carry out the manufacturing steps for treatments near or on-site. Learn more in the July edition of our Regulatory Round-up: lnkd.in/eJzKsy-e

Regulatory update 🔔: MHRA CEO Lawrence Tallon welcomes UK government's Life Sciences Sector Plan The document, in which the CGT Catapult plays a key part, sets out a vision and action plan to drive growth, innovation, and better health outcomes across the UK. Learn more: lnkd.in/eJzKsy-e #ATMPs

Learn more about our exciting collaboration with Plurify to develop technology that improves the purity of #CellTherapies - making them safer, more efficacious and less costly to produce 👇

The Centre of Excellence in Regulatory Science & Innovation for Advanced Therapies (CERSI-AT) is on LinkedIn! Coordinated by us & Birmingham Health Partners CRSI, CERSI-AT ensures the UK has a world-leading regulatory environment for ATMP innovation. Follow today: www.linkedin.com/showcase/108...

We're gathering insights from stakeholders across the ecosystem to better understand the current landscape and challenges of applying AI in the development and assessment of #ATMPs. Share your insights with us in this short survey: lnkd.in/eBkPyYa8 #AdvancedTherapies #AI #CellTherapy #GeneTherapy

Applications are now open to our competition for Scottish academics looking for support to develop a target product profile (TPP) and quality target product profile (QTPP) for their #AdvancedTherapy or vaccine 🚨 Application deadline: 26th August 2025 Apply today: ct.catapult.org.uk/p/tpp

In the first investment from the CGT Catapult as part of the Cross-Catapult Investment Pilot, Spliceor has received funding to accelerate the pre-clinical development of its trans-splicing #GeneTherapy platform for liver cancer. Learn more: lnkd.in/e4h9xNkQ @catapultnetwork.bsky.social

See our response to the recent publication of the Government's Life Sciences Sector Plan, learn more about the plan and how advanced therapies can play a key part: ct.catapult.org.uk/news/cgt-cat... #LifeSciencesSectorPlan #ATMPs #LifeSciences

Regulatory update 🔔: MHRA leads safe use of AI in healthcare as first country in new global network. The move puts the MHRA at the centre of global efforts to get trusted AI tools safely into clinics faster Learn more in the June edition of our Regulatory Round-up: ow.ly/ABbp50Woakh

Subscribe to the Cell and Gene Therapy Catapult newsletter today 📩 Click this link to get the latest news, industry reports and event announcements sent straight to your inbox: lnkd.in/e4xpEHKX #CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies

Regulatory update 🔔: New Post-Market Surveillance regulation took effect across Great Britain in June 2025, requiring medical device manufacturers to proactively monitor the safety and performance of their products once on the market. Learn more in our June Regulatory Round-up: ow.ly/KyGe50WkU3z

🧬 @cgtcatapult.bsky.social led a major foresighting cycle identifying 130+ capabilities needed in a rapidly digitising biotech sector, which involved academia, industry, and tech experts. 🔗 loom.ly/0A9Vmz0 #LifeSciences #Biotech

How can we bridge academia and industry to advance #CellAndGeneTherapy? 🔬 Last month, @cgtcatapult.bsky.social’s Dan Gibson & @ucl.ac.uk’s Qasim Rafiq explored the challenges & opportunities in scaling advanced manufacturing. Watch the fireside chat 🔥 loom.ly/g0xTB_o

Thinking of enrolling in a Level 7 apprenticeship? Next week the Advanced Therapies Apprenticeship Community (ATAC) are hosting a webinar which will spotlight three successful Level 7 apprenticeships that have been used by members of ATAC since 2019. Register now: ow.ly/g9lr50WjwgE

It was great to visit the Catapult Gene and Cell Therapy site in Stevenage last week for the opening of the new Digital Automation Testbeds 🧬 Thanks to the Minister of State for Science, Research, and Innovation, Lord Patrick Valance for attending 👨‍🔬

CAR T Vision, an international coalition uniting healthcare stakeholders to improve patient access to CAR T-cell therapy, has launched their CAR T Vision and Roadmap Report. The report outlines recommendations to help the industry increase patient access to CAR T therapy: ow.ly/VZia50WaC8h

Regulatory update 🔔: European Pharmacopoeia Commission (EPC) adopts mycoplasma general chapter and monographs, updated to incorporate latest analytical developments. Learn more about the specifics of the revised general chapter in the May edition of our Regulatory Round-up: ow.ly/xCB650W8SGY

@nicolemather.bsky.social delivered a powerful talk on how AI & digital technologies can transform ATMP production at our CGT Catapult & Alliance for Regenerative Medicine Industrialisation workshop today! Key areas included: data standardisation, platform scale out & flexible automation.

Yesterday, Lord Vallance, Minister of State for Science, Research and Innovation, opened our Digital and Automation Testbeds that have been developed to improve #AdvancedTherapy manufacturing. Learn more: ct.catapult.org.uk/news/science... #ATMPs #CellTherapy #GeneTherapy #AdvancedTherapies

Regulatory update 🔔 The @fda.gov has approved Zevaskyn an autologous cell sheet-based gene therapy, indicated for treatment of wounds in adult & paediatric patients with recessive dystrophic epidermolysis bullosa. Learn more in the May edition of our monthly Regulatory Round-up: ow.ly/PXsA50W5m3H

We had the pleasure of welcoming Tom Adeyoola, the new Executive Chair of @innovateuk.bsky.social, to our site at Guy's Hospital this week. Tom toured our process and analytical development laboratories, learning how revolutionary advanced therapies improve health and support UK economic growth.

Following the ATI North event last month, we reflect on key takeaways from the “Digitally Driven” panel chaired by @nicolemather.bsky.social. Discussion explored how digital tools are helping to reduce the cost of #ATMPs and unlock patient-centric therapies. Read the blog: ow.ly/u0Fy50VZQQC

How can we balance commercial viability of ATMPs with patient accessibility & affordability? This afternoon’s panel at ATI North with Panos Kefalas, our Director of Access Strategy, will examine the UK’s ATMP funding & reimbursement structure, exploring how the UK remains globally competitive.

A discussion filled with inspiring digital expertise! At the end of the session, @nicolemather.bsky.social, asked panellists what is their wish for the future from a digital perspective. Kevin Vela, CGT Catapult, answered: “That the industry continues to collaborate and share data to innovate.”

In the next session at ATI North, CGT Catapult Non-Executive Director, Nicole Mather, will facilitate discussion between digital leaders in the advanced therapies industry - exploring how emerging innovations are being harnessed to overcome manufacturing bottlenecks. @nicolemather.bsky.social

We’ve been getting ready for the first Advanced Therapies Integrates North today in Edinburgh! Looking forward to the day ahead, with opening remarks from CGT Catapult’s Jacqueline Barry and a fireside chat with Kevin Bruce, RoslinCT, on ‘Advanced Therapies: Patient to Population Impact’. #ATMPs

Matthew Durdy, our Chief Executive, attended the #WhiteHouse Cell and Gene Therapy Forum last week which brought together government, researchers, charities and industry to discuss how life-changing #advancedtherapies can be more widely adopted. #WhiteHouseCGT #cellandgenetherapy